These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34493137)

  • 1. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review.
    Schattenberg JM; Anstee QM; Caussy C; Bugianesi E; Popovic B
    Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1253-1266. PubMed ID: 34493137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    Tokushige K; Ikejima K; Ono M; Eguchi Y; Kamada Y; Itoh Y; Akuta N; Yoneda M; Iwasa M; Yoneda M; Otsuka M; Tamaki N; Kogiso T; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K
    J Gastroenterol; 2021 Nov; 56(11):951-963. PubMed ID: 34533632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
    Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.
    Leoni S; Tovoli F; Napoli L; Serio I; Ferri S; Bolondi L
    World J Gastroenterol; 2018 Aug; 24(30):3361-3373. PubMed ID: 30122876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of nonalcoholic fatty liver disease in the Middle East.
    Sanai FM; Abaalkhail F; Hasan F; Farooqi MH; Nahdi NA; Younossi ZM
    World J Gastroenterol; 2020 Jul; 26(25):3528-3541. PubMed ID: 32742124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparing for the NASH Epidemic: A Call to Action.
    Kanwal F; Shubrook JH; Younossi Z; Natarajan Y; Bugianesi E; Rinella ME; Harrison SA; Mantzoros C; Pfotenhauer K; Klein S; Eckel RH; Kruger D; El-Serag H; Cusi K
    Gastroenterology; 2021 Sep; 161(3):1030-1042.e8. PubMed ID: 34416976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
    Lazarus JV; Ekstedt M; Marchesini G; Mullen J; Novak K; Pericàs JM; Roel E; Romero-Gómez M; Ratziu V; Tacke F; Cortez-Pinto H; Anstee QM;
    J Hepatol; 2020 Jan; 72(1):14-24. PubMed ID: 31518646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Libman H; Jiang ZG; Tapper EB; Reynolds EE
    Ann Intern Med; 2019 Aug; 171(3):199-207. PubMed ID: 31382287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparing for the NASH Epidemic: A Call to Action.
    Kanwal F; Shubrook JH; Younossi Z; Natarajan Y; Bugianesi E; Rinella ME; Harrison SA; Mantzoros C; Pfotenhauer K; Klein S; Eckel RH; Kruger D; El-Serag H; Cusi K
    Diabetes Care; 2021 Sep; 44(9):2162-2172. PubMed ID: 34312182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey.
    Nadolsky K; Cryer DR; Articolo A; Fisher T; Schneider J; Rinella M
    Ann Med; 2023 Dec; 55(1):2211349. PubMed ID: 37171239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
    Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
    Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Spengler EK; Loomba R
    Mayo Clin Proc; 2015 Sep; 90(9):1233-46. PubMed ID: 26219858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
    Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
    Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver Disease: Nonalcoholic Fatty Liver Disease.
    Cooper J; Baumgartner K; Smith A; St Louis J
    FP Essent; 2021 Dec; 511():29-35. PubMed ID: 34855339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparing for the NASH epidemic: A call to action.
    Kanwal F; Shubrook JH; Younossi Z; Natarajan Y; Bugianesi E; Rinella ME; Harrison SA; Mantzoros C; Pfotenhauer K; Klein S; Eckel RH; Kruger D; El-Serag H; Cusi K
    Obesity (Silver Spring); 2021 Sep; 29(9):1401-1412. PubMed ID: 34365735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.
    Loomba R; Lim JK; Patton H; El-Serag HB
    Gastroenterology; 2020 May; 158(6):1822-1830. PubMed ID: 32006545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.
    Anstee QM; Hallsworth K; Lynch N; Hauvespre A; Mansour E; Kozma S; Marino JP; Bottomley J; Piercy J; Higgins V
    JHEP Rep; 2022 Jan; 4(1):100411. PubMed ID: 34977520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
    Kuchay MS; Choudhary NS; Mishra SK; Misra A
    Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
    Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
    Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.